JPRN-jRCT2080220972已完成2 期
A Multicentre, Open-label, Extension Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy
obelpharma Co. Ltd.0 个研究点目标入组 88 人开始时间: 2010年1月21日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 4age old 至 <= 15age old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque PsoriasisModerate-to-Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code: 10071117Term: Plaque psoriasis Class: 10040785CTIS2022-502361-15-00Bristol Myers Squibb International Corporation1,659
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with PsoriasisModerate-to-Severe Plaque PsoriasisEUCTR2019-000612-29-FIBristol-Myers Squibb International Corporation1,560
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with PsoriasisEUCTR2019-000612-29-ESBristol-Myers Squibb International Corporation1,950
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with PsoriasisEUCTR2019-000612-29-HUBristol-Myers Squibb International Corporation1,950
进行中（未招募）
1 期
ong-Term Safety and Efficacy of BMS-986165 in Subjects with PsoriasisEUCTR2019-000612-29-PLBristol-Myers Squibb International Corporation1,560